2004
DOI: 10.1016/j.jaad.2002.09.002
|View full text |Cite
|
Sign up to set email alerts
|

Prolonged evolution of a lentigo maligna

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
1

Year Published

2005
2005
2020
2020

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 30 publications
0
1
1
Order By: Relevance
“…The absence of an invasive component, particularly in an LM first documented at the age of 22 years and excised 29 years later, can be considered to be another peculiar finding of our patient. Bevona et al [7] reported LM melanoma developing approximately 40 years after the first onset of LM, but this case differs from ours inasmuch as it was characterized by multiple recurrences after previous surgical and nonsurgical treatments.…”
Section: Commentcontrasting
confidence: 68%
“…The absence of an invasive component, particularly in an LM first documented at the age of 22 years and excised 29 years later, can be considered to be another peculiar finding of our patient. Bevona et al [7] reported LM melanoma developing approximately 40 years after the first onset of LM, but this case differs from ours inasmuch as it was characterized by multiple recurrences after previous surgical and nonsurgical treatments.…”
Section: Commentcontrasting
confidence: 68%
“…Second, anti‐CD117 therapies, such as STI‐571 (Gleevec ® ), may be used as an adjuvant therapy for primary superficial spreading melanomas, including lentigo maligna melanoma (LMM) and melanoma in situ . Surgical excision will remain the treatment of choice in these cases, but often it is challenging to achieve a true negative margin and the recurrence rate for LMM is very high 18 . An anti‐CD117 agent will help turn off the proliferative signal and hopefully induce apoptosis of atypical melanocytes as observed in vitro 19 .…”
Section: Discussionmentioning
confidence: 99%